이상혈색소증 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 유형별(지중해빈혈, 겸상적혈구증, 기타 헤모글로빈 변이), 진단별, 치료법별, 지역별, 경쟁별(2020-2030년)
Hemoglobinopathies Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Type (Thalassemia, Sickle Cell Disease, Other Hemoglobin Variants), By Diagnosis, By Therapy, By Region, Competition, 2020-2030F
상품코드:1881501
리서치사:TechSci Research
발행일:2025년 11월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 이상혈색소증 시장은 2024년에 84억 4,000만 달러로 평가되었으며, 2030년까지 CAGR 12.7%로 성장하여 172억 9,000만 달러에 달할 것으로 예측됩니다.
이상혈색소증은 적혈구 내 산소 수송에 필수적인 헤모글로빈 분자의 구조 또는 생성에 이상이 생기는 유전성 혈액질환군을 말합니다. 이들 질환 세계 시장은 주로 유전성 질환의 전 세계 유병률 증가와 진단 기술 및 치료 개입의 획기적인 발전으로 인해 주도되고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
84억 4,000만 달러
시장 규모 : 2030년
172억 9,000만 달러
CAGR : 2025-2030년
12.7%
가장 빠르게 성장하는 부문
겸상적혈구증
최대 시장
북미
주요 시장 촉진요인
세계 이상혈색소증 시장은 이러한 유전성 질환의 전 세계 유병률 증가와 새로운 유전자 기반 치료법의 지속적인 출현으로 인해 큰 영향을 받고 있습니다. 유병률의 증가는 진단, 치료 및 지속적인 치료가 필요한 환자층의 확대에 직접적으로 기여하여 전체 시장 수요를 확대하는 데 기여하고 있습니다.
주요 시장 과제
새로운 첨단 치료법, 특히 유전자 치료와 골수 이식에 따른 막대한 비용이 세계 이상혈색소증 시장 발전에 큰 장벽이 되고 있습니다. 이러한 치료법은 획기적인 결과를 가져올 수 있는 잠재력을 가지고 있지만, 종종 엄청난 비용이 수반되는 경우가 많습니다.
주요 시장 동향
인공지능(AI)은 중요한 트렌드이며, 복잡한 데이터 분석을 효율화하여 이상혈색소증의 진단 정확도와 효율성을 향상시키고 있습니다. 이 기술은 유전정보와 의료기록을 활용하여 질병을 보다 신속하고 정확하게 파악할 수 있습니다.
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 이상혈색소증 시장 전망
시장 규모 및 예측
금액별
시장 점유율과 예측
유형별(지중해빈혈, 겸상적혈구증, 기타 헤모글로빈(Hb) 변이)
진단별(지중해빈혈{혈액 검사, 유전자 검사, 출생전 유전자 검사, 착상전 유전자 진단, 전기영동, 기타}, 겸상적혈구증{혈액 검사, 유전자 검사, 출생전 유전자 검사, 전기영동, 기타}, 기타{혈액 검사, 유전자 검사, 출생전 유전자 검사, 전기영동, 기타})
The Global Hemoglobinopathies Market , valued at USD 8.44 Billion in 2024, is projected to experience a CAGR of 12.7% to reach USD 17.29 Billion by 2030. Hemoglobinopathies represent a group of inherited blood disorders characterized by abnormalities in the structure or production of the hemoglobin molecule, crucial for oxygen transport within red blood cells. The global market for these conditions is primarily driven by the increasing worldwide prevalence of these genetic disorders and significant advancements in diagnostic technologies and therapeutic interventions.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 8.44 Billion
Market Size 2030
USD 17.29 Billion
CAGR 2025-2030
12.7%
Fastest Growing Segment
Sickle Cell Disease
Largest Market
North America
Key Market Drivers
The global hemoglobinopathies market is significantly influenced by the increasing worldwide prevalence of these genetic disorders and the continuous emergence of novel and gene-based therapies. The rising prevalence contributes directly to a larger patient pool requiring diagnosis, treatment, and ongoing care, thereby expanding the overall market demand. According to The Lancet Haematology, in June 2023, the number of people living with sickle cell disease globally increased by 41.4% from 2000 to 7.74 million in 2021, highlighting a substantial and growing patient population. This demographic shift necessitates enhanced healthcare resources and drives investments in therapeutic solutions.
Key Market Challenges
The substantial cost associated with novel, advanced therapies, particularly gene therapies and bone marrow transplantation, represents a significant impediment to the global hemoglobinopathies market's expansion. These treatments, while offering the potential for transformative outcomes, are often accompanied by prohibitively high price tags. For instance, according to the Sickle Cell Disease Association of America, in December 2023, the list price for Casgevy, a gene therapy for sickle cell disease, was estimated at $2.2 million, while Lyfgenia, another gene therapy for the same condition, was estimated at $3.1 million.
Key Market Trends
Artificial intelligence is a significant trend, enhancing diagnostic precision and efficiency for hemoglobinopathies by streamlining complex data analysis. This technology leverages genetic information and medical records for quicker and more accurate disorder identification. While its potential is substantial, challenges remain; according to the National Institutes of Health, in August 2024, the best-performing AI models achieved only 21 percent accurate diagnoses from patient-written genetic condition descriptions, emphasizing areas for refinement. Despite these, AI proves impactful in personalized monitoring.
Key Market Players
Sangamo Therapeutics, Inc.
Pfizer, Inc. (Global Blood Therapeutics, Inc.)
bluebird bio, Inc.
Emmaus Medical, Inc.
Novartis AG
Prolong Pharmaceuticals, LLC
Sanofi S.A. (Bioverativ Inc.)
Gamida Cell Ltd.
Celgene Corporation
Abbott Laboratories, Inc.
Report Scope:
In this report, the Global Hemoglobinopathies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Other {Blood Test, Genetic Test, Prenatal Genetic Test, Electrophoresis, Others}
Hemoglobinopathies Market , By Therapy:
Thalassemia {Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant, Others}
Sickle Cell Disease {Blood Transfusion, Hydroxyurea, Bone Marrow Transplant, Others}
Other {Blood Transfusion, Hydroxyurea, Iron Chelation Therapy, Bone Marrow Transplant, Others}
Hemoglobinopathies Market , By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Hemoglobinopathies Market .
Available Customizations:
Global Hemoglobinopathies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Hemoglobinopathies Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants)
5.2.3. By Therapy (Thalassemia {Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant, Others}, Sickle Cell Disease {Blood Transfusion, Hydroxyurea, Bone Marrow Transplant, Others}, Other {Blood Transfusion, Hydroxyurea, Iron Chelation Therapy, Bone Marrow Transplant, Others})
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Hemoglobinopathies Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Diagnosis
6.2.3. By Therapy
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Hemoglobinopathies Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Diagnosis
6.3.1.2.3. By Therapy
6.3.2. Canada Hemoglobinopathies Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Diagnosis
6.3.2.2.3. By Therapy
6.3.3. Mexico Hemoglobinopathies Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Diagnosis
6.3.3.2.3. By Therapy
7. Europe Hemoglobinopathies Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Diagnosis
7.2.3. By Therapy
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Hemoglobinopathies Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Diagnosis
7.3.1.2.3. By Therapy
7.3.2. France Hemoglobinopathies Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Diagnosis
7.3.2.2.3. By Therapy
7.3.3. United Kingdom Hemoglobinopathies Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Diagnosis
7.3.3.2.3. By Therapy
7.3.4. Italy Hemoglobinopathies Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Diagnosis
7.3.4.2.3. By Therapy
7.3.5. Spain Hemoglobinopathies Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Diagnosis
7.3.5.2.3. By Therapy
8. Asia Pacific Hemoglobinopathies Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Diagnosis
8.2.3. By Therapy
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Hemoglobinopathies Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Diagnosis
8.3.1.2.3. By Therapy
8.3.2. India Hemoglobinopathies Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Diagnosis
8.3.2.2.3. By Therapy
8.3.3. Japan Hemoglobinopathies Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Diagnosis
8.3.3.2.3. By Therapy
8.3.4. South Korea Hemoglobinopathies Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Diagnosis
8.3.4.2.3. By Therapy
8.3.5. Australia Hemoglobinopathies Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Diagnosis
8.3.5.2.3. By Therapy
9. Middle East & Africa Hemoglobinopathies Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Diagnosis
9.2.3. By Therapy
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Hemoglobinopathies Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Diagnosis
9.3.1.2.3. By Therapy
9.3.2. UAE Hemoglobinopathies Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Diagnosis
9.3.2.2.3. By Therapy
9.3.3. South Africa Hemoglobinopathies Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Diagnosis
9.3.3.2.3. By Therapy
10. South America Hemoglobinopathies Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Diagnosis
10.2.3. By Therapy
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Hemoglobinopathies Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Diagnosis
10.3.1.2.3. By Therapy
10.3.2. Colombia Hemoglobinopathies Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Diagnosis
10.3.2.2.3. By Therapy
10.3.3. Argentina Hemoglobinopathies Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Diagnosis
10.3.3.2.3. By Therapy
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Hemoglobinopathies Market : SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Sangamo Therapeutics, Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Pfizer, Inc. (Global Blood Therapeutics, Inc.)
